{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:26:57Z","timestamp":1792686417075,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/iop.0b013e3182392f29","type":"journal-article","created":{"date-parts":[[2011,12,21]],"date-time":"2011-12-21T04:56:05Z","timestamp":1324443365000},"page":"85-89","source":"Crossref","is-referenced-by-count":49,"title":["Refractory Squamous Cell Carcinoma of the Conjunctiva Treated With Subconjunctival Ranibizumab (Lucentis)"],"prefix":"10.1097","volume":"28","author":[{"given":"Paul T.","family":"Finger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly J.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0039-6257(05)80054-2","article-title":"Ocular surface squamous neoplasia.","volume":"39","author":"Lee","year":"1995","journal-title":"Surv Ophthalmol"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00003226-200310000-00015","article-title":"Ocular surface squamous neoplasia: a review.","volume":"22","author":"Basti","year":"2003","journal-title":"Cornea"},{"key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0002-9394(89)90655-7","article-title":"Long-term results of cryotherapy on malignant epithelial tumors of the conjunctiva.","volume":"107","author":"Peksayar","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/bjo.83.1.98","article-title":"Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: analysis of 60 cases.","volume":"83","author":"Tunc","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2010.01.032","article-title":"Tumor-associated lymphangiogenesis in the development of conjunctival squamous cell carcinoma.","volume":"117","author":"Heindl","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0039-6257(00)00210-1","article-title":"Chemotherapy for eye cancer.","volume":"45","author":"Wilson","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/bjo.2006.092734","article-title":"Topical mitomycin chemotherapy for malignant conjunctival and corneal neoplasia.","volume":"90","author":"Finger","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0161-6420(97)30055-4","article-title":"Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience.","volume":"104","author":"Frucht-Pery","year":"1997","journal-title":"Ophthalmology"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00055735-199808000-00006","article-title":"Antimetabolites in ocular surface neoplasia.","volume":"9","author":"Majmudar","year":"1998","journal-title":"Curr Opin Ophthalmol"},{"key":"R12-1-20210129","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2010.03.052","article-title":"Subconjunctivalperilesional recombinant interferon for ocular surface squamous neoplasia: a 10-year review.","volume":"117","author":"Karp","year":"2010","journal-title":"Ophthalmology"},{"key":"R13-1-20210129","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.ophtha.2007.10.039","article-title":"Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.","volume":"115","author":"Schechter","year":"2008","journal-title":"Ophthalmology"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/bjo.2004.063339","article-title":"Treatment of biopsy proved conjunctival intraepithelial neoplasia with topical interferon alfa-2b.","volume":"89","author":"Esquenazi","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0161-6420(00)00389-4","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea.","volume":"107","author":"Yeatts","year":"2000","journal-title":"Ophthalmology"},{"key":"R16-1-20210129","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/bjo.84.3.268","article-title":"Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil.","volume":"84","author":"Midena","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2147\/OPTH.S9709","article-title":"5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea.","volume":"4","author":"Al-Barrag","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.survophthal.2009.06.004","article-title":"Radiation therapy for orbital tumors: concepts, current use and ophthalmic radiation side effects.","volume":"54","author":"Finger","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/IOP.0b013e31820d872f","article-title":"Electron beam radiation for conjunctival squamous carcinoma.","volume":"27","author":"Graue","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.clinthera.2006.11.015","article-title":"Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.","volume":"28","author":"Shih","year":"2006","journal-title":"Clin Ther"},{"key":"R21-1-20210129","first-page":"3186","article-title":"Subconjunctival Anti VEGF for Conjunctival Intraepithelial and Invasive Neoplasia.","volume":"3","author":"Zaki","year":"2009","journal-title":"Australian J Bas Appl Sci"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/bjo.2008.156489","article-title":"Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension.","volume":"93","author":"Teng","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R23-1-20210129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archopht.121.2.168","article-title":"High-frequency ultrasonographic evaluation of conjunctival intraepithelial neoplasia and squamous cell carcinoma.","volume":"121","author":"Finger","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","article-title":"Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.","volume":"57","author":"Pelle","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ajo.2009.06.015","article-title":"The diagnostic value of exfoliative cytology vs histopathology for ocular surface squamous neoplasia.","volume":"148","author":"Semenova","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"R29-1-20210129","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short-and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.ajo.2010.01.015","article-title":"Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery.","volume":"149","author":"Galor","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":"Preliminary results of subconjunctival bevacizumab in primary pterygium excision.","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICO.0b013e31818d382d","article-title":"Effect of subconjunctival bevacizumab on primary pterygium.","volume":"28","author":"Teng","year":"2009","journal-title":"Cornea"},{"key":"R35-1-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08820530902801106","article-title":"Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.","volume":"24","author":"Mauro","year":"2009","journal-title":"Semin Ophthalmol"}],"container-title":["Ophthalmic Plastic & Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IOP.0b013e3182392f29","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:30:23Z","timestamp":1786048223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002341-201203000-00001"}},"subtitle":["A Two-Year Study"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/iop.0b013e3182392f29","relation":{},"ISSN":["0740-9303"],"issn-type":[{"value":"0740-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}